JP7820364B2 - 抗ｃｄ４７抗体及び使用方法 - Google Patents

抗ｃｄ４７抗体及び使用方法

Info

Publication number
JP7820364B2
JP7820364B2 JP2023519252A JP2023519252A JP7820364B2 JP 7820364 B2 JP7820364 B2 JP 7820364B2 JP 2023519252 A JP2023519252 A JP 2023519252A JP 2023519252 A JP2023519252 A JP 2023519252A JP 7820364 B2 JP7820364 B2 JP 7820364B2
Authority
JP
Japan
Prior art keywords
antibody
cdr
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023519252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544294A5 (https=
JP2023544294A (ja
Inventor
ワン，ジン－タン
ツェン，チー－リン
ジアン，ウェイ－ドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Henlius Biologics Co Ltd
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Original Assignee
Shanghai Henlius Biologics Co Ltd
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biologics Co Ltd, Shanghai Henlius Biopharmaceutical Co Ltd, Shanghai Henlius Biotech Inc filed Critical Shanghai Henlius Biologics Co Ltd
Publication of JP2023544294A publication Critical patent/JP2023544294A/ja
Publication of JP2023544294A5 publication Critical patent/JP2023544294A5/ja
Application granted granted Critical
Publication of JP7820364B2 publication Critical patent/JP7820364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023519252A 2020-09-28 2021-09-28 抗ｃｄ４７抗体及び使用方法 Active JP7820364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/118320 2020-09-28
CN2020118320 2020-09-28
PCT/CN2021/121314 WO2022063316A1 (en) 2020-09-28 2021-09-28 Anti-cd47 antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2023544294A JP2023544294A (ja) 2023-10-23
JP2023544294A5 JP2023544294A5 (https=) 2024-10-07
JP7820364B2 true JP7820364B2 (ja) 2026-02-25

Family

ID=80844512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519252A Active JP7820364B2 (ja) 2020-09-28 2021-09-28 抗ｃｄ４７抗体及び使用方法

Country Status (9)

Country Link
US (1) US20230279110A1 (https=)
EP (1) EP4217397A4 (https=)
JP (1) JP7820364B2 (https=)
KR (1) KR20230079393A (https=)
CN (1) CN116323675A (https=)
AU (1) AU2021346729A1 (https=)
CA (1) CA3191835A1 (https=)
WO (1) WO2022063316A1 (https=)
ZA (1) ZA202304167B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102757518B1 (ko) * 2020-12-07 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
KR20250172692A (ko) 2021-12-21 2025-12-09 에프비디 바이올로직스 리미티드 조작된 SIRPα 변이체 및 이의 사용 방법
WO2024140998A2 (en) * 2022-12-29 2024-07-04 Shanghai Henlius Biotech, Inc. Anti-pdl1 antibodies, multispecific antibodies and methods of use
IL321674A (en) * 2022-12-29 2025-08-01 Shanghai Henlius Biotech Inc Anti-cd47 antibodies and methods of use
EP4490201A4 (en) 2023-05-31 2026-03-11 Fbd Biologics Ltd CD47/PD-L1 Targeted Protein Complex and Its Methods of Use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508030A (ja) 2016-01-11 2019-03-28 フォーティー セブン，インコーポレイテッド ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体
WO2019144895A1 (en) 2018-01-24 2019-08-01 Nanjing Legend Biotech Co., Ltd. Anti-cd47 antibodies that do not cause significant red blood cell agglutination
US20200048369A1 (en) 2016-10-26 2020-02-13 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190112374A1 (en) * 2010-05-14 2019-04-18 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
EP3454900A4 (en) * 2016-05-09 2020-01-29 Celgene Corporation CD47 ANTIBODIES AND METHODS OF USE
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
CN111087470B (zh) * 2020-01-19 2022-05-10 中国人民解放军第四军医大学 一种抗人CD47单克隆抗体7G4mAb及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508030A (ja) 2016-01-11 2019-03-28 フォーティー セブン，インコーポレイテッド ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体
US20200048369A1 (en) 2016-10-26 2020-02-13 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
WO2019144895A1 (en) 2018-01-24 2019-08-01 Nanjing Legend Biotech Co., Ltd. Anti-cd47 antibodies that do not cause significant red blood cell agglutination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HemaSphera，Vol. 4, Suppl. 1，2020年，pp. 1019-1020

Also Published As

Publication number Publication date
US20230279110A1 (en) 2023-09-07
KR20230079393A (ko) 2023-06-07
ZA202304167B (en) 2023-10-25
WO2022063316A1 (en) 2022-03-31
EP4217397A4 (en) 2025-01-08
EP4217397A1 (en) 2023-08-02
JP2023544294A (ja) 2023-10-23
CN116323675A (zh) 2023-06-23
AU2021346729A1 (en) 2023-05-11
CA3191835A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
JP7730821B2 (ja) 抗ｔｉｇｉｔ抗体及び使用方法
JP7820364B2 (ja) 抗ｃｄ４７抗体及び使用方法
US20250019459A1 (en) Anti-msln antibodies and methods of use
WO2024061306A1 (en) Anti-b7h3 antibodies and methods of use
US20240043558A1 (en) Anti-gpc3 antibodies, multispecific antibodies and methods of use
JP2026501590A (ja) 抗ｐｄｌ１抗体、多重特異性抗体、及び使用方法
WO2022223018A1 (en) Anti-gpc3 antibodies and methods of use
RU2852190C1 (ru) Антитела против cd47 и способы их применения
WO2024140993A2 (en) Anti-cd47 antibodies and methods of use
WO2024061297A1 (en) Anti-b7h3 antibodies, multispecific antibodies and methods of use
US20230340098A1 (en) Anti-garp/tgf-beta antibodies and methods of use
WO2024140997A2 (en) Anti-pdl1 antibodies and methods of use
JP2026500781A (ja) 抗ｐｄｌ１／ｖｅｇｆ抗体及び使用方法
HK40094105A (zh) 抗cd47抗体及使用方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240926

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260212

R150 Certificate of patent or registration of utility model

Ref document number: 7820364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150